Summary: In the same way you can walk into a high-end clothing store and be fitted for a custom-tailored suit, you may soon have the opportunity to go to your doctor's office and receive a custom-tailored treatment for your ailments. It's called personalized medicine — therapeutics and diagnostics that are targeted for specific ethnic, familial and other demographic groups based on their genetic profiles, certain biomarkers and environmental exposure. Not only are these treatments likely to be more effective, but they also have the potential to reduce adverse side effects and improve your quality of life. Highlights: * How can personalized medicine be beneficial for all stakeholders — businesses and consumers alike — as well as society as a whole? * Why is personalized medicine becoming more attractive to pharmaceutical companies than the so-called blockbuster drugs that have long bolstered their bottom line? * How can life sciences companies attain a high return on investment from personalized treatments in spite of the fact that the markets for them are smaller than they are for most conventional drugs? How can health plans rationalize covering the expense of personalized therapeutics for their members? * Health care innovations can challenge the status quo, and personalized medicine is unlikely to be an exception. What kind of disruption may this technology cause, and how slowly or rapidly might it be adopted? Guests: Terry Hisey, vice chairman, U.S. Life Sciences leader, Deloitte LLP Paul Keckley, Ph.D., executive director, Deloitte Center for Health Solutions, Deloitte LLP
